Key result
Prolonged-release lappaconitine hydrobromide blocks ventricular sodium, potassium, and calcium channels with a 1:3:7 IC50 ratio.
Why the study?
Initial findings on the effect of prolonged-release lappaconitine hydrobromide on myocardial ion currents were obtained only recently and required further clarification and detailed analysis.
Does the active substance of prolonged-release lappaconitine hydrobromide inhibit sodium, potassium, and calcium ion currents in isolated mouse ventricular myocytes and CHO-K1 cells?
Does the active substance of prolonged-release lappaconitine hydrobromide inhibit sodium, potassium, and calcium ion currents in isolated mouse ventricular myocytes and CHO-K1 cells?
Answers are grounded in this paper and cite their sources.
Simultaneous blockade of sodium, potassium, and calcium channels in a 1:3:7 IC50 ratio may explain the balance between antiarrhythmic efficacy and low proarrhythmic potential of prolonged-release lappaconitine hydrobromide.
Initial results regarding the effect of prolonged-release lappaconitine hydrobromide on myocardial ion currents were obtained only recently and require further clarification and detailed analysis in future studies. Objective. To conduct a detailed assessment of the effect of the active substance of prolonged-release lappaconitine hydrobromide (AIERLH) on ion currents mediated by channels characteristic of ventricular cardiomyocytes. Materials and Methods. The whole-cell patch-clamp technique was used to study the effects of AIERLH on currents in isolated mouse ventricular myocytes and in the CHO-K1 heterologous expression system. Results. The ratio of half-maximal inhibitory concentrations (IC50) for the fast sodium current, the rapid delayed-rectifier potassium current, and the slow calcium current in ventricular cardiomyocytes treated with AIERLH is 1:3:7. These findings partially explain the extremely low proarrhythmic potential of AIERLH during effective antiarrhythmic therapy with the drug Allaforte®. Conclusion. The simultaneous blockade of multiple ion channels may ensure a balance between the efficacy and safety of AIERLH.
No takes yet. Share an insight, caveat, or question.
Abramochkin et al. (2026) studied Arrhythmia (preclinical ion channel assessment). Prolonged-release lappaconitine hydrobromide active substance (AIERLH) was evaluated on Ratio of half-maximal inhibitory concentrations (IC50) for fast sodium current, rapid delayed-rectifier potassium current, and slow calcium current. Prolonged-release lappaconitine hydrobromide (AIERLH) inhibited fast sodium, rapid delayed-rectifier potassium, and slow calcium currents in ventricular cardiomyocytes with an IC50 ratio of 1:3:7.
Synapse has enriched 10 related papers. Consider them for comparative context: